AMGN : Analysis & Opinions

  1. Bull of the Day: Quintiles (Q) - Bull of the Day

    March 5, 2014
    Bull of the Day: Quintiles (Q) - Bull of the Day
  2. Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - ...

    January 8, 2014
    Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - Industry Outlook
  3. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  4. A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  5. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  6. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  7. Bull of the Day: Biogen Idec (BIIB) - Bull of the Day

    August 28, 2013
    Bull of the Day: Biogen Idec (BIIB) - Bull of the Day
  8. Taper Coming Despite Weak Data? - Ahead of Wall Street

    August 26, 2013
    This morning's weak Durable Goods report and Friday's New Home sales number raise doubts about the economy.
  9. Benzinga Market Primer: Thursday, August 1: Futures Up On Europe ...

    August 1, 2013
    Futures Higher on Economic Data U.S. equity futures are significantly up in early pre-market trade based on strong Asian ...
  10. Qiagen Grows CDx Portfolio - Analyst Blog

    July 15, 2013
    Qiagen gains FDA approval for the therascreen EGFR test.
  11. Stock Market News for July 15, 2013 - Market News

    July 15, 2013
    Benchmarks posted marginal gains on Friday following better-than-expected results of few banking companies.
  12. Amgen - Servier Ink Deal - Analyst Blog

    July 10, 2013
    This deal should help Amgen strengthen its cardiovascular pipeline.
  13. Estarylla Lot Recalled by Novartis' Sandoz - Analyst Blog

    July 8, 2013
    Sandoz recently announced that it is voluntarily recalling one lot of its oral contraceptive drug, Estarylla (norgestimate ...
  14. Amgen Puts Onyx Pharmaceuticals In Play

    July 2, 2013
    An unsolicited $120/share bid has sent Onyx soaring and rival bidders circling.
  15. Onyx Pharma Turns Down Amgen offer - Analyst Blog

    July 1, 2013
    Onyx rejected Amgen's takeover bid.
  16. Stock Market News for July 1, 2013 - Market News

    July 1, 2013
    Benchmarks ended a three day gaining streak on Friday as fears of the Federal Reserve scaling back the bond buying program ...
  17. Novartis' Sandoz Progresses with Biosimilars - Analyst Blog

    June 26, 2013
    Novartis announced that its generic arm, Sandoz, has initiated a phase III study for its biosimilar version of Amgen's (AMGN) ...
  18. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  19. Apremilast Data Presented by Celgene - Analyst Blog

    June 14, 2013
    Celgene presented data from the PALACE 3 study on apremilast.
  20. 3 Impressive Biotech ETFs Crushing the Market - ETF News And ...

    June 11, 2013
    Rotate into the outperforming biotech sector with these three ETFs.
  21. 10 Picks from 2 Strong Sectors

    June 10, 2013
    As we enter the bumpy summer months, large-cap US domestic stocks and health-care names are on Louis Navellier's list, and ...
  22. Amgen Provides Long-Term Update - Analyst Blog

    February 13, 2013
    Amgen (AMGN) recently provided an update on its long-term strategy. The company said that it intends to focus on the discovery ...
  23. UCB, Amgen Discontinue Study - Analyst Blog

    February 12, 2013
    UCB (UCBJF) and Amgen Inc. (AMGN) recently announced their decision to discontinue a phase III program being conducted with ...
  24. Amgen Misses on EPS, Guides Above - Analyst Blog

    January 24, 2013
    Amgen (AMGN) reported fourth quarter 2012 earnings of $1.39 per share, 4 cents below the Zacks Consensus Estimate. Earnings, ...
  25. Management Expands at AstraZeneca - Analyst Blog

    January 17, 2013
    AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At the same ...
  26. Canadian Approval for BMY's Drug - Analyst Blog

    January 16, 2013
    Good news flowed in at Bristol-Myers Squibb (BMY) from Canada when Health Canada, the federal department responsible for ...
  27. Biogen Submits Hemophilia B BLA - Analyst Blog

    January 8, 2013
    Biogen Idec (BIIB) recently submitted a Biologics License Application (BLA) seeking US Food and Drug Administration (FDA) ...
  28. BioMimetic's Pipeline Progresses - Analyst Blog

    January 7, 2013
    Biotechnology company, BioMimetic Therapeutics, Inc. (BMTI) recently announced that it has started enrolling patients for ...
  29. Positive Data on Actelion Candidate - Analyst Blog

    December 19, 2012
    Actelion (ALIOF) recently announced positive results from a phase II study on its S1P1 modulator, ponesimod. Actelion is ...
  30. Abbott's Humira's Label Expanded - Analyst Blog

    November 28, 2012
    Abbott Labs (ABT) recently received approval for yet another indication of Humira (adalimumab). The European Commission approved ...
  31. Biotech ETFs: A Fiscal Cliff Safe Haven? - ETF News And Commentary

    November 16, 2012
    With the election over, many investors assumed that one of the key risk events for U.S. markets was past us. However, this ...
  32. AZN's Forxiga Gets EU Approval - Analyst Blog

    November 15, 2012
    Recently, AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that their type II diabetes candidate, Forxiga (dapagliflozin) ...
  33. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  34. Beat and Raise Quarter for Amgen - Analyst Blog

    October 24, 2012
    Amgen (AMGN) continued its strong performance in 2012 with third quarter earnings coming in at $1.66 per share, 23 cents ...
  35. Amgen and Other Healthcare Stocks Making Big Moves on October ...

    October 19, 2012
    The market is having a bad day so far: the Nasdaq has slipped 1.6%; the S&P 500 is trading down 1%; and the Dow is down 1.1%. ...
  36. Stock Market News for October 17, 2012 - Market News

    October 17, 2012
    Better-than expected quarterly results combined with a couple of positive domestic reports guided the benchmarks into the ...
  37. Abbott Reports Encouraging HCV Data - Analyst Blog

    October 16, 2012
    Abbott Laboratories (ABT) recently announced promising data from the phase IIb Aviator trial evaluating the combination of ...
  38. New Indication for Abbott's Humira - Analyst Blog

    October 4, 2012
    Abbott Labs (ABT) recently announced that it has received approval for an additional indication of Humira (adalimumab) from ...
  39. Novartis Progresses with AIN457 - Analyst Blog

    October 1, 2012
    Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced phase II data on its pipeline candidate, AIN457 ...
  40. Another Approval for Amgen's Prolia - Analyst Blog

    September 25, 2012
    The US Food and Drug Administration (FDA) recently granted approval to Amgen's (AMGN) Prolia (denosumab) for an additional ...
  41. The Week In Healthcare

    August 31, 2012
    Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally.
  42. Takeda Halts GAMMA Study in Japan - Analyst Blog

    August 16, 2012
    Takeda Pharmaceutical Company Limited (TKPYY) and its subsidiary Millennium, recently decided to stop its ganitumab phase ...
  43. 5 Familiar Stocks to Sell (or Short)! - Investment Ideas

    August 3, 2012
    Like so many people around the planet, I tuned into some Olympic action over the weekend. Ever since childhood, I have enjoyed ...
  44. Portfolio Pruning 101

    July 27, 2012
    MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take profits on ...
  45. Amgen Beats, Raises Guidance - Analyst Blog

    July 27, 2012
    Amgen (AMGN) continued its strong performance in 2012 with second quarter earnings coming in at $1.82 per share, 31 cents ...
  46. FDA Label Expansion for Erbitux - Analyst Blog

    July 9, 2012
    Bristol-Myers Squibb Company (BMY) and partner Eli Lilly & Company (LLY) recently announced that they have received approval ...
  47. DaVita to Settle Epogen Lawsuit - Analyst Blog

    July 6, 2012
    Recently, DaVita Inc. (DVA) agreed to pay $55 million in a bid to settle a lawsuit, indicting it for overuse of Amgen Inc's ...
  48. Dr. Reddy's & Merck Serono Team Up - Analyst Blog

    June 8, 2012
    Dr. Reddy's Laboratories Ltd. (RDY) recently announced a collaboration agreement with Merck Serono, a division of Merck KGaA ...
  49. Abbott Presents Data on Humira - Analyst Blog

    June 7, 2012
    Abbott Labs (ABT) recently presented phase III data on its blockbuster drug, Humira, from two studies. While ABILITY-2 is ...
  50. ilent Pays A Hefty Price For A Fixer-Upper Diagnostics Company

    May 22, 2012
    Agilent is paying up to get into the increasingly crowded diagnostics market.
  51. Biotech ETFs Hitting Highs

    May 17, 2012
    Biotech ETFs are hitting all-time highs and XBI looks like the best of the group. Because the ETF is already up 25% in 2 ...
  52. AstraZeneca Searches For Answers

    May 3, 2012
    AstraZeneca has an opportunity to do something big when it brings in a new CEO.
  53. 3 Biotechs on the Verge

    April 11, 2012
    The risks are huge, but well worth the potential rewards, writes MoneyShow.com senior editor Igor Greenwald. Let’s ...
  54. 4 ETFs On Fire Right Now

    February 3, 2012
    The commodities market had some of the best-performing ETFs of January.
  55. Big Buys In Share Buybacks

    January 27, 2012
    Record corporate profits and super low interest rates are resulting in a shrinking market environment and a rise in share ...
  56. 4 Stocks To Contemplate Before Thursday

    January 24, 2012
    Here are four companies that will be releasing their earnings on January 26th.
  57. The Haunted Houses Investors Won't Enter

    October 28, 2011
    Investors' fear to even consider that certain investments can limit gains and diversification.
  58. 7 Stocks To Contemplate Over The Weekend

    October 21, 2011
    Here are seven companies that will be releasing their earnings on October 24.
  59. Be Your Own Venture Capitalist With These Stocks

    September 16, 2011
    By doing some digging, there are ways for the average joe to become his/her own venture capital fund.
  60. Seattle Genetics – And Now The Hard Bit

    August 23, 2011
    Seattle Genetics got a much-needed FDA approval, but the sales ramp could be challenging for the stock.
  61. Dendreon's Bull Story In Intensive Care

    August 10, 2011
    Dendreon shocks bulls with a poor revenue ramp for Provenge.
  62. 10 Drug Firms to Profit on Biosimilars

    July 28, 2011
    Over the next five years, the market for "biosimilars" is forecast to climb to $10 billion worldwide, as many brand-name ...
  63. Vical Gets Some Validation

    July 19, 2011
    Vical gets a small victory with a partnership for its CMV drug.
  64. Icahn's Additions

    June 1, 2011
    Take a peek at some of Icahn Capital LP's holdings to see what positions Carl Icahn has added to.
  65. A Deal At Last For Sanofi And Genzyme

    February 18, 2011
    Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
  66. 6 Oversold Stocks To Watch

    February 18, 2011
    Let's take a look at a few stocks that have recently entered oversold territory because these could be candidates for a short-term ...
  67. Can Savient Soar On One Specialty Drug?

    September 16, 2010
    Obtaining FDA approval is only part of the story for this one-drug company.
  68. Market News That Seems Promising - But Isn't

    September 13, 2010
    Not all good news is created equal. Find out how some positive stock market news can actually be bad news for investors.
  69. Sanofi Ups The Pressure On Genzyme

    September 1, 2010
    Sanofi has decided to make its intentions public and ratchet up the pressure on GENZ management.
  70. Biosimilars - The Next Generic Honeypot

    August 10, 2010
    With the first biosimilar approval in over a decade, a major new market for generics could be on the horizon
  71. Getting In On Growth At A Great Price

    July 5, 2010
    Here are some growth-oriented stocks with below-market average P/Es that investors can pick up during this shaky market to ...
  72. Forest Labs Is Green With Cash

    April 16, 2010
    Look beyond the trees and at the entire Forest, and what you see is a great risk reward opportunity.
  73. Searching For Growth And Value in Biotech

    March 9, 2010
    With health care reform ever present in the news, what are the prospects for biotech firms?
  74. Forest Labs' Oh-So-Healthy Balance Sheet

    January 26, 2010
    This company has a pristine capital structure and a stockpile of cash, but the best part is that its stock is cheap.
  75. Great Expectations For Apple

    January 25, 2010
    Apple will be the most closely watched company to report quarterly earnings January 25, but several other big names are also ...
  76. Large Cap Biotech Earnings Preview

    October 16, 2009
    Biotech stocks traditionally fare well through recessions. We'll see if that holds true.
  77. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others.
  78. Stock Buybacks Fall Off A Cliff

    July 1, 2009
    We take a look at the stock repurchase report from S&P, to see what is signals for the economy.
  79. Two More Reasons To Diversify

    June 3, 2009
    GM and Citigroup being removed from the DJIA should cause investors to focus on diversification.
  80. Convertible Securities In Today's Market

    April 30, 2009
    John Calamos, the father of convertible investing, moderated a panel on convertible bonds at the Milken Global Conference ...
  81. Dark Horse Candidates To Enter The Dow

    March 4, 2009
    The DJIA is sure to be rebalanced over the next year as some members teeter on bankruptcy or face falling from the index.
  82. 5 Biotech Stocks To Watch In 2009

    December 30, 2008
    When the market starts to look sickly, can you turn to Biotechs to inject health into your portfolio? Here are five stocks ...
  83. ETFs A Job Hunting Tool For New Grads

    November 21, 2008
    Sector-specific ETFs could point the way to job opportunities for recent college grads.
  84. Healthcare's Balanced ETF

    October 6, 2008
    The Rydex S&P Equal Weight Health Care ETF has outperformed many rival funds by taking a balanced approach to the sector.
  85. Biotech's Best And Worst

    April 14, 2008
    Not all biotech stocks are built the same. Now could be the time to make exits on the winners and go bargain hunting.
  86. Genentech's Avastin Disappoints

    April 11, 2008
    Genentech released earnings that drew mixed reaction from the Street, but on closer inspection the quarter is a clear miss. ...
  87. Leap Of Faith Healing (MEDX, PDLI, AMLN)

    August 8, 2007
    Make the leap with three pharmaceutical companies who require investor courage but could provide a healthy return.
  88. Small Caps For Big Cures (VRTX, VRX, MLNM)

    July 27, 2007
    These three companies are on the cutting edge, but can they carve out big returns for investors?
  89. Go Ask Alice (DNA, AMGN, CELG)

    March 15, 2007
    Biotech is not without its risks, but its definitely one of the sectors to search for bargains in.
  90. Can Genentech Go Higher?

    April 13, 2006
    A look at the recent quarter of one of the leading biotech companies.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center